Kardigan, Inc. is a clinical-stage precision therapeutics company. It is developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Its pipeline of products includes Danicamtiv, Ataciguat and Tonlamarsen. Danicamtiv is an investigational oral cardiac atrial and ventricular myosin activator for the treatment of genetic dilated cardiomyopathy caused by pathogenic variants in myosin heavy chain 7 (MYH7) and titin, the common sarcomeric gene variants. Ataciguat is an investigational oral, once-daily soluble guanylate cyclase activator aimed at slowing the progression of calcific aortic valve stenosis in patients with moderate diseases. Tonlamarsen is an investigational liver-directed antisense oligonucleotide administered once-monthly via subcutaneous injection, targeting hepatic angiotensinogen for the management of blood pressure in acute severe hypertension post-hospitalization. Prolaio is a clinical intelligence platform.
公司代碼KARD
公司名稱Kardigan Inc
上市日期Jun 18, 2026
CEOGianakakos (Tassos Anastasios)
員工數量420
證券類型Ordinary Share
年結日Jun 18
公司地址506 Carnegie Center Drive, Suite 201
城市PRINCETON JUNCTION
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編08540
電話14155733220
網址http://www.kardigan.bio
公司代碼KARD
上市日期Jun 18, 2026
CEOGianakakos (Tassos Anastasios)